Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Buy
CRBU is expected to release CAR-T trial results by year-end. The company is currently trading around its cash value.
According to last week’s report, results are “on par” with FDA-approved therapies in the space (but with far better scalability), and they are already in discussions with the FDA.
From discussions with Grok Chat and Claude – if data supports a Phase 3 move, we could be looking at a 3–5x re-rating from current levels.
Speculative, but I think this could 🚀